Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold

Go back to Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia

November 24, 2021 4:15 PM EST

WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 (which consists of MMA-101 plus ImmTOR) for the treatment of patients with methylmalonic acidemia (MMA).

On November 23, Selecta received a letter from the FDA issuing a clinical hold in order to obtain additional information on the chemistry, manufacturing... More